BIRAD – Bar Ilan University Research and Development Company Ltd. (BIRAD), and the biodesign lab headed by Dr. Ido Bachelet at Bar Ilan University, announced that BIRAD has entered into an evaluation agreement with Pfizer Inc. This agreement is focused on gaining a better understanding into DNA nanorobots as potential carriers of different proteins for possible new treatments. The terms of the agreement were not disclosed.

The evaluation work of BIRAD and Pfizer brings together the pioneering work of university researchers in the field of DNA nanorobots with Pfizer’s expertise in the design and delivery of small molecule and biotherapeutics.

Nanorobots turn from science fiction to applied solutions
“Humanity has not succeeded yet in developing a machine that can communicate directly with biologic structures, biologic processes and affect it by doing so,” said Dr. Bachelet. “However, the development of such machines may have dramatic consequences on our lives and may enable us to help manage and control processes in our body just as they are forming. At our lab, we are developing nanorobots from the most basic biological building block, DNA, and we hope to someday use these nanorobots for medical and industrial purposes.”

Bar-Ilan Research & Development Company Ltd. (BIRAD) was established in order to disseminate and to effectively commercialize intellectual property developed at BIU by transforming Bar Ilan University-based discoveries into applied initiatives that strengthen the economy, promote prosperity and improve lives.

Bar Ilan University is the fastest growing institution of higher education in Israel. In the last decade, an increased focus on natural sciences has resulted in the University’s growth from two science-based faculties to four, including a faculty of Engineering, School of Medicine and the establishment of Israel’s largest Nanotechnology center.

BIRAD attributes high importance to Industry – Academic interactions. We hope that the formation of unique collaborations will maximize University research potential, ultimately transforming this potential into practical applications.